Retention Rate of Ixekizumab in Psoriatic Arthritis: A Real-World Study
Journal of Personalized Medicine · 03.07.2024 · 14 (7) · 716
DOI: 10.3390/jpm14070716 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Personalized Medicine, online erschienen am 03.07.2024. Verfasst von Elisa Bellis und 11 weiteren Autor:innen. Beteiligte Einrichtung: Academic Rheumatology Centre, Department of Clinical and Biological Sciences, University of Turin, AO Mauriziano di Torino, 10128 Turin, Italy. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
We aimed to examine the drug retention rate (DRR) of the interleukin-17 inhibitor ixekizumab in a real-world monocentric cohort of psoriatic arthritis (PsA) patients and to assess the predictors of drug discontinuation. Consecutive PsA patients who underwent treatment with ixekizumab from October 2019 to February 2023 were enrolled in this observational, retrospective, monocentric study. Clinical records were assessed at baseline and throughout the follow-up period. We collected sociodemographic data, smoking habits, body mass index, the presence of Human Leukocyte Antigen B27, comorbidities, disease involvement and duration, previous therapy, discontinuation of ixekizumab, reasons for discontinuation, and adverse events (AEs). DRR was evaluated as time to drug discontinuation and assessed through Kaplan–Meier curves. Baseline factors predicting drug discontinuation were investigated through logistic regression models. Eighty PsA patients were included in this study. Ixekizumab was administered at a dose of 160 mg by subcutaneous injection at baseline, followed by 80 mg every four weeks thereafter. Ixekizumab had a 38-month-cumulative DRR of 43.8%, accounting for both inefficacy and AEs. When considering only inefficacy, the DRR was 62.6%. Comorbidities (p = 0.665), obesity (p = 0.665), smoking (p = 0.884), disease duration ≤ 2 years (p = 0.071), axial (p = 0.131) and skin involvement (p = 0.460), and previous therapies, including conventional synthetic (p = 0.504) and biological (p = 0.474) Disease-Modifying Antirheumatic Drugs (bDMARDs), as well as the number of previous bDMARDs or targeted synthetic Disease-Modifying Antirheumatic Drugs (tsDMARDs), did not significantly affect the DRR (p = 0.349). Multivariate analysis found no independent predictors of drug discontinuation. The most frequent AEs leading to discontinuation were skin reactions; no severe infections were observed. In our real-world study, comorbidities, disease duration, and previous therapies did not affect the DRR of ixekizumab. Ixekizumab had a favorable safety profile, with no severe AEs observed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Academic Rheumatology Centre, Department of Clinical and Biological Sciences, University of Turin, AO Mauriziano di Torino, 10128 Turin, Italy.
- Rheumatology Unit, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, 67100 L'Aquila, Italy.
ORCID-Profile: Elisa Bellis, Piero Ruscitti, Denise Donzella, Mariele Gatto
Zitieren
APA
Bellis, E., Ruscitti, P., Donzella, D., Crepaldi, G., Data, V., Gammino, M., Gatto, M., Guardo, V., Lomater, C., Marucco, E., Saracco, M., & Iagnocco, A. (2024). Retention Rate of Ixekizumab in Psoriatic Arthritis: A Real-World Study. Journal of Personalized Medicine, 14(7), 716. https://doi.org/10.3390/jpm14070716
Vancouver
Bellis E, Ruscitti P, Donzella D, Crepaldi G, Data V, Gammino M, et al. Retention Rate of Ixekizumab in Psoriatic Arthritis: A Real-World Study. Journal of Personalized Medicine. 2024;14(7):716. doi:10.3390/jpm14070716
BibTeX
@article{Bellis2024,
author = {Bellis, Elisa and Ruscitti, Piero and Donzella, Denise and Crepaldi, Gloria and Data, Valeria and Gammino, Marinella and Gatto, Mariele and Guardo, Valeria and Lomater, Claudia and Marucco, Elena and Saracco, Marta and Iagnocco, Annamaria},
title = {Retention Rate of Ixekizumab in Psoriatic Arthritis: A Real-World Study},
journal = {Journal of Personalized Medicine},
year = {2024},
volume = {14},
number = {7},
pages = {716},
doi = {10.3390/jpm14070716}
}
EUVIMED